RhumbLine Advisers’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$956K Buy
37,463
+5,827
+18% +$175K ﹤0.01% 2299
2026
Q2
$835K Buy
+31,636
New +$732K ﹤0.01% 2433
2025
Q2
– Sell
-27,127
Closed -$58.6K – 4280
2025
Q1
$58.6K Buy
27,127
+1,571
+6% +$5.62K ﹤0.01% 3536
2024
Q4
$108K Buy
25,556
+5,008
+24% +$31.3K ﹤0.01% 3458
2024
Q3
$235K Buy
20,548
+10,009
+95% +$122K ﹤0.01% 3155
2024
Q2
$113K Buy
+10,539
New +$137K ﹤0.01% 3487

Other funds holding ANRO

RhumbLine Advisers's ANRO Position: Q3 2026 in Review

RhumbLine Advisers increased its Alto Neuroscience (ANRO) stake by 18% in Q3 2026, buying an estimated $175K and bringing the position to 37,463 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

RhumbLine Advisers first reported a position in ANRO in Q2 2024 and has held it in 6 quarters since. 133 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • RhumbLine Advisers held 37,463 shares of Alto Neuroscience worth $956K as of Q3 2026.
  • RhumbLine Advisers bought 5,827 Alto Neuroscience shares in Q3 2026, an estimated $175K.
  • Alto Neuroscience made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2299 holding.
  • RhumbLine Advisers first reported a position in Alto Neuroscience in Q2 2024 and has held it in 6 quarters since.
  • 133 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.